Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Sep:129:102790.
doi: 10.1016/j.ctrv.2024.102790. Epub 2024 Jun 22.

Locally advanced and metastatic endometrial cancer: Current and emerging therapies

Alixe Salmon  1 , Alizée Lebeau  2 , Sylvie Streel  1 , Adriane Dheur  3 , Sophie Schoenen  3 , Frédéric Goffin  3 , Elodie Gonne  1 , Frédéric Kridelka  3 , Athanasios Kakkos  3 , Christine Gennigens  4
Affiliations
Free article
Review

Locally advanced and metastatic endometrial cancer: Current and emerging therapies

Alixe Salmon et al. Cancer Treat Rev. 2024 Sep.
Free article

Abstract

Until recently, patients diagnosed with locally advanced and metastatic endometrial cancer faced significant challenges in their treatment due to limited options and poor prognostic outcomes. The sequencing of tumors has been a major advancement in its management. It has led to The Cancer Genome Atlas classification currently used in clinical practice and the initiation of several clinical trials for innovative treatments targeting principally signaling pathways, immune checkpoints, DNA integrity, growth factors, hormonal signaling, and metabolism. Numerous clinical trials are investigating a combinatorial approach of these targeted therapies to counter tumoral resistance, cellular compensatory mechanisms, and tumor polyclonality. This review provides a comprehensive overview of historical, current, and promising therapies in advanced and metastatic endometrial cancer. It particularly highlights clinical research on targeted and hormonal therapies, but also immunotherapy, reflecting the evolving landscape of treatment modalities for this disease.

Keywords: Advanced disease; Endometrial cancer; Metastatic; Personalized treatment; Targeted therapy.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Christine Gennigens = All support for the present manuscrit: no disclosures. Grant/contracts: Astra-Zeneca, GSK, Deciphera. Consulting fees: Ipsen, GSK, MSD. Honoraria for lectures: MSD, BMS, Ipsen, Pfizer, Pharmamar, Astra-Zeneca, GSK. Support for meetings and/or travel: Ipsen, Pharmamar, Pfizer, MSD, GSK, Astra-Zeneca. Participation on a data safety monitoring board or advisory board: MSD, BMS, Ipsen, Astra-Zeneca. GSK, Eisai. Others authors – No conflict of interest.

LinkOut - more resources